Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.

ABSTRACT: NEPA is the only fixed combination antiemetic, comprised of an NK₁ RA (netupitant) and a 5-HT₃ RA (palonosetron). In the first head-to-head trial to compare NK₁ RA-containing regimens, a single oral dose of NEPA was non-inferior to a 3-day aprepitant/granisetron (APR/GRAN) regimen for the primary endpoint of overall (0-120 hours) complete response (no emesis/no rescue). This pre-specified analysis evaluates the efficacy of NEPA versus APR/GRAN in the subset of Chinese patients in the study. In addition, efficacy in patients at greatest emetic risk receiving high-dose cisplatin (≥70 mg/m² ) was explored. Chemotherapy-naïve patients with solid tumors in this randomized, double-blind study received either a single dose of NEPA prior to cisplatin-bas

SUBMITTER: Chang J 

PROVIDER: S-EPMC7367622 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature